Sun Pharmaceutical (SUNPHARMA) — concall transcript

📢 Key Event
Sun Pharma reports Q3 FY25 results with 10.5% sales growth, 24.1% adjusted profit growth, and specialty segment expansion, while litigation and R&D plans remain key focus areas.

🔄 What Changed
Adjusted net profit grew 24.1% YoY excluding a one-time INR3,162 million settlement; standalone depreciation fell to INR300 crores from INR400 crores; R&D as % of sales dropped to 6.3%, below guidance; India growth of 14% was volume-led, not price-driven.

🔮 What's Next
None provided beyond general objectives; R&D budget to be updated next fiscal year; capital allocation to prioritize specialty products; no specific launch timeline for LEQSELVI beyond dependence on April judgment; inventory dynamics may affect next quarter’s specialty sales.

💡 Investor Takeaway
The company is shifting focus to specialty growth and volume-driven expansion in India and emerging markets, while navigating litigation, pricing pressures, and R&D delays, with capital directed toward higher-margin opportunities.

Sun Pharmaceutical reported Q3 FY25 consolidated sales of ₹134,369 million, up 10.5% YoY, with EBITDA at ₹40,090 million (15.3% growth) and adjusted net profit of ₹32,196 million (24.1% growth), excluding a ₹3,162 million opioid litigation settlement. India formulation sales rose 13.8%, contributing to 14% overall India growth driven by volume and new products, not price. U.S. sales dipped 1% YoY to US$474 million, but specialty revenue grew to US$325 million, half from the U.S. R&D spend was INR8,450 million (6.3% of sales), below guidance, with FY25 expected to stay under 7% of sales. Depreciation fell to INR300 crores standalone due to asset write-offs, while capital focus remains on strategic specialty investments. No forward guidance was given beyond general objectives.

📄 View Original Announcement (PDF)

📊 Stock Analysis — SUNPHARMA ✨ Ask AI About This

About Sun Pharmaceutical Industries Ltd (SUNPHARMA)

Healthcare · Pharmaceuticals · Listed on BSE

Market Cap: ₹4,63,179.62 Cr P/E: 38.3 ROE: 14.6% ROCE: 18.7% Div Yield: 0.83%

View full SUNPHARMA stock details →

📡 Get AI alerts when SUNPHARMA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track SUNPHARMA — Free

💡 Ask AI about this filing

"How will LEQSELVI launch timing impact future U.S. specialty revenue?" "What is the expected timing for R&D spend increase above 7% of sales?" "How does the company plan to offset pricing pressure in Japan?"

Ask AI Free →

📊 More SUNPHARMA filings

See all SUNPHARMA filings →

🔥 Also filed on 31 December 2024

INFY Infosys Ltd concall transcript INDIGO Interglobe Aviation Ltd concall transcript M&M Mahindra & Mahindra Ltd concall transcript SBIN State Bank of India concall transcript ULTRACEMCO UltraTech Cement Ltd concall transcript BEL Bharat Electronics Ltd concall transcript

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when SUNPHARMA files new disclosures

Track SUNPHARMA filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track SUNPHARMA — Free

Free account · 2 AI queries/day

About · Privacy Policy · Terms of Service · Pricing

Today's Announcements · Screener · Insights · AI Chat

Data provided by CMOTS Internet Technologies Pvt Ltd